Opendata, web and dolomites


Function of DUX4 in skeletal muscle and non-muscle tissues

Total Cost €


EC-Contrib. €






Project "DUX4" data sheet

The following table provides information about the project.


Organization address
city: LEIDEN
postcode: 2333 ZA

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Netherlands [NL]
 Total cost 177˙598 €
 EC max contribution 177˙598 € (100%)
 Programme 1. H2020-EU.1.3.2. (Nurturing excellence by means of cross-border and cross-sector mobility)
 Code Call H2020-MSCA-IF-2017
 Funding Scheme MSCA-IF-EF-RI
 Starting year 2018
 Duration (year-month-day) from 2018-07-01   to  2020-09-29


Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    ACADEMISCH ZIEKENHUIS LEIDEN NL (LEIDEN) coordinator 177˙598.00


 Project objective

Somatic expression of the retrogene DUX4 in skeletal muscle is associated with the development of the common myopathy facioscapulohumeral muscular dystrophy (FSHD). As FSHD patients mainly present with muscular symptoms, research in the FSHD field has focused on unraveling the functional consequences of DUX4 expression in skeletal muscle. Research on DUX4 expression in non-muscle tissues is limited, but increasing evidence suggests a biological function for DUX4 in somatic tissues. I aim to characterize DUX4 expression in non-muscle tissues, to determine the genome-wide transcriptional consequences of DUX4 expression, to identify DUX4 target genes in these tissues, and to establish whether treatment with DUX4 antisense oligonucleotides negatively impacts somatic tissues in which DUX4 has a biological function. First, I will use a combination of quantitative reverse transcriptase PCR, immunofluorescence staining, and flow cytometry to establish which tissues and what cell types express DUX4 in human and mouse. Next, I will use the innovative technique of single-cell RNA sequencing to determine the autonomous and non-autonomous functional consequences of DUX4 expression in DUX4-positive tissues. In parallel, to establish which genes and pathways are direct targets of DUX4 and whether tissue-specific differences exist, I will employ DUX4-chromatin immunoprecipitation sequencing. Finally, I will determine the effect of DUX4 suppression in vitro and in vivo. The proposed work will provide in depth analysis into the biological function of DUX4 in somatic tissues, contribute to the long-standing enigma in the field why FSHD presents as a muscle-specific disease, and provide guidance to DUX4-targeted therapies that are currently being developed.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "DUX4" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email ( and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "DUX4" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.1.3.2.)

iRhomADAM (2020)

Uncovering the role of the iRhom2-ADAM17 interaction in inflammatory signalling

Read More  

NPsVLCD (2019)

Natural Product-Inspired Therapies for Leishmaniasis and Chagas Disease

Read More  

NaWaTL (2020)

Narrative, Writing, and the Teotihuacan Language: Exploring Language History Through Phylogenetics, Epigraphy and Iconography

Read More